Pasithea Therapeutics, a biotechnology company focused on the discovery, research and development of treatments for central nervous system (CNS) disorders, has signed a contract with WuXi STA, a subsidiary of WuXi AppTec, to manufacture the active pharmaceutical ingredient (API) for its macrocyclic, next-generation MEK Inhibitor, PAS-004 (formerly CIP-137401). After the completion of the pre-clinical testing and animal toxicology studies, GMP manufacturing is the final major requirement to su...